Ex-CEO and major shareholder Dr. Burkhard Wittek sues PULSION for continuation of salary payments due to alleged unlawful dismissal
Initial value of the claim: EUR 617,760
The initial value of the claim of EUR 617,760 has meanwhile been reduced to EUR 128,700 by the responsible district court München I. The period of notice agreed with former CEO Dr. Burkhard Wittek was one month. The company defends itself against the claim, in particular as it wishes to avoid payments lacking legal grounds to a major shareholder at the expense of the other shareholders. A date for the hearing has not yet been announced.
PULSION Medical Systems SE
PULSION Medical Systems AG, founded in 1990, has become one of the leading specialists for intelligent medical diagnosis and therapy management systems and has been listed on the Stock Exchange in Frankfurt since 2001. The repeated development of innovative product lines in the medtech field is the basis for creation and expansion of the attractive disposable business with sterile products and pharmaceuticals.
The business unit PULSION Intensive Care covering intensive care medicine, perioperative medicine and emergency medicine focuses on the management of cardiovascular and organ functions of critically ill patients.
Products and activities of the business unit PULSION Pharma are directed at the diagnosis and therapy management of organ and tissue perfusion in ophthalmology, surgery and hepatology.
PULSION products are marketed worldwide via own sales channels or secondary distribution. All products are certified with the CE mark which is basis for marketing in the EU and some other countries. The US-American FDA approval and the Japanese market approval have been issued for selected product lines.
Further information about PULSION is available at www.pulsion.com.